Lyell Immunopharma, Inc. (LYEL) analyst actions
Rating and price-target actions on LYEL in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the LYEL overview →
2 measured LYEL analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma | Press release | +2.46% | +3.93% | |
| Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee | Press release | — | -0.61% |
Keep exploring
More LYEL: earnings → · SEC filings → · LYEL overview →